COO’s Blog

May 2019 In this video blog, Tammy talks about how Centralized Monitoring won’t solve all your Quality Management issues, the changing role of the CRA because of RBM, the first readout of the E8 (R1) guidance and much more… What’s new and exciting in the Sector? April 15th 2019: We’re finally starting to get a readout from some of…

Read More

Klifo/TRI Protocol Risk Assessment Workshop – 18th June, Copenhagen

ICH E6 (R2) GCP regulations explicitly require a risk-based approach to quality management. However, the challenges faced by small and mid-sized research organisations in effectively adopting Risk-Based Monitoring (RBM) and ensuring R2 compliance can be significant. In this interactive workshop we will take you through the practical steps involved in conducting an effective and compliant Protocol Risk Assessment. In…

Read More

1st review of the E8 (R1) Guidance

Free Webinar – Thursday 20th June, 3pm BST The recently published E8 (R1) draft guidance has some important information for those involved in protocol design, including the identification of factors critical to quality and risk management in clinical trials. In this session, Tammy Finnigan, COO, with take you through the key elements of the guidance and talks about the…

Read More

Risk Assessment & Risk Management Tool Demo – 2nd July

Duncan Hall, CEO of TRI will show you how the new Risk Assessment and Risk Management tool delivers an end-to-end process for identifying, monitoring and managing clinical trial risks. From the initial identification of risks as part of the Protocol Risk Assessment, right the way through to the end of the trial, this tool documents changes to risks, captures…

Read More

Copy of Risk Assessment & Risk Management Tool Demo – 25th July

Duncan Hall, CEO of TRI will show you how the new Risk Assessment and Risk Management tool delivers an end-to-end process for identifying, monitoring and managing clinical trial risks. From the initial identification of risks as part of the Protocol Risk Assessment, right the way through to the end of the trial, this tool documents changes to risks, captures…

Read More

TRI Webinar Channel

Go to our new webinar channel Over the last few years we’ve run over 25 different webinars to over 1,000 people. We often get requests for the recordings, so now we’ve made it easy for anyone and everyone to watch them.  There is a treasure trove of useful information, industry insights and great advice in there, so go ahead…

Read More

FDA RBM Q&A Guidance for Industry

In March 2019 the FDA released their RBM Q&A Guidance for Industry. If you haven’t read it yet, the link is below, it makes for some interesting reading. The focus of this guidance is to provide further clarification and suggestions on how best to implement risk based approaches to monitoring. Interestingly the guidance focuses very heavily on the risk…

Read More

The R2 story – what is it, why it’s needed & why now?

Lots of people don’t understand what R2 is and why it’s needed. And unless you understand the fundamental reasons for its creation and adoption, it’s easy to dismiss it as ‘just more bureaucracy’.  But it isn’t.  It’s much more important than that, and here’s the reasons why. The way clinical trials are conducted has changed dramatically over the last…

Read More

Steven Law is our new SVP of Sales

Steven Law has been appointed as the new SVP of Sales for TRI. Steven is a global sales leader with over 32 years of management experience within the IT software and services industry in sales, marketing and business development roles both directly and through channel partners. Over the past 25 years Steven has been working with some of the…

Read More

Phil M’Caw new TRI CFO

Phil M’Caw has been appointed as the new Chief Financial Officer of TRI. Phil has over 25 years of hands-on experience of financial and commercial management in several sectors with growth businesses having international footprints. He trained as Chartered Accountant with KPMG London before moving into management consultancy with KPMG and then into roles in industry. He has worked…

Read More

Mike Lewis announced as Chair of TRI

Mike is Chair of 4 public and private healthcare companies and has 30 years global Health industry experience having previously held senior roles at Align Technology (Amsterdam), Boston Scientific (Paris), C.R. Bard (USA), Sybron (Switzerland) and Becton Dickinson (UK) and was President of Gambro (Sweden) leading the £3bn buyout. Having spent 22 of the last 25 years living and…

Read More

TRI raises multi-million growth funding

TRI raises multi-million growth funding from Octopus Investments to expand its Risk-Based Monitoring platform for clinical trials 15th October 2018, LONDON, UK – TRI, a leading global provider of Risk-Based Monitoring (RBM) solutions for clinical trials, has completed a growth capital fundraise to accelerate development of its core technology platform, OPRA and expand its international presence. Founded in 2014,…

Read More

The best questions from 3 years of webinars and training

Over the past three years we’ve trained over 1,000 people in webinars, on-line training sessions and face-to-face sessions.  Most of that training has been done by Tammy Finnigan, our COO.  She’s the person ‘on the hook’ to answer when someone asks a difficult question.  Fortunately for us, she has a wealth of experience in Quality Management, Risk Based Monitoring,…

Read More

Q&A 33 : How should known Risks be handled?

“How should known Risks be handled? Risks are always identified as potential facts right? I mean errors done with the ICF for example (as not timely approved by ECs although used) are already deviations, not risks.” ICH GCP Ref: 5.0 ; 5.0.2 I like to think of this using the simple worked example below. Fact: Known Information e.g. the…

Read More